Arcutis Biotherapeutics Inc
ARQT14.300USD
+0.010+0.07%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.70BValor de mercado
PerdaP/L TTM
Mais detalhes de Arcutis Biotherapeutics Inc Empresa
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Informações da empresa
Código da empresaARQT
Nome da EmpresaArcutis Biotherapeutics Inc
Data de listagemJan 31, 2020
CEOMr. Todd Franklin Watanabe
Número de funcionários342
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 31
Endereço3027 Townsgate Road
CidadeWESTLAKE VILLAGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal91361
Telefone18054185006
Sitehttps://arcutis.com/
Código da empresaARQT
Data de listagemJan 31, 2020
CEOMr. Todd Franklin Watanabe
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
26.43K
+40.42%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
Investidores
Investidores
Proporção
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
Tipos de investidores
Investidores
Proporção
Investment Advisor
32.24%
Investment Advisor/Hedge Fund
31.96%
Hedge Fund
29.96%
Private Equity
7.39%
Research Firm
4.30%
Individual Investor
2.19%
Venture Capital
1.84%
Sovereign Wealth Fund
0.45%
Bank and Trust
0.42%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
477
132.39M
111.07%
-21.95M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Simplify Health Care ETF
4.4%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
SPDR S&P Biotech ETF
0.55%
First Trust Small Cap Growth AlphaDEX Fund
0.49%
Direxion Daily S&P Biotech Bull 3X Shares
0.31%
Federated Hermes MDT Small Cap Core ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.27%
ProShares Ultra Nasdaq Biotechnology
0.19%
Invesco Nasdaq Biotechnology ETF
0.19%
Inspire Small/Mid Cap ESG ETF
0.17%
Ver Mais
Simplify Health Care ETF
Proporção4.4%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.93%
SPDR S&P Biotech ETF
Proporção0.55%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.49%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.31%
Federated Hermes MDT Small Cap Core ETF
Proporção0.28%
First Trust Small Cap Core Alphadex Fund
Proporção0.27%
ProShares Ultra Nasdaq Biotechnology
Proporção0.19%
Invesco Nasdaq Biotechnology ETF
Proporção0.19%
Inspire Small/Mid Cap ESG ETF
Proporção0.17%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
